Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
Not Confirmed
Not Confirmed
27-29 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Industry Trade Show
Not Confirmed
27-29 January, 2026
Digital content
NEWS #PharmaBuzz
07 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251031980313/en/A2-Biotherapeutics-Presents-Initial-Safety-and-Efficacy-Data-from-Ongoing-Phase-12-EVEREST-2-Study-Including-First-Report-of-a-Complete-Response-to-CAR-T-Cell-Therapy-in-a-Patient-with-NSCLC
03 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251001069413/en/A2-Bio-to-Present-Early-Safety-and-Efficacy-Data-from-EVEREST-2-Study-during-2025-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer
08 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250904676127/en/A2-Biotherapeutics-Presents-Data-from-Ongoing-Phase-12-EVEREST-2-Study-During-the-International-Association-for-the-Study-of-Lung-Cancer-2025-World-Conference-on-Lung-Cancer
26 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250624143809/en/A2-Bio-Announces-First-Patient-Dosed-in-DENALI-1-Phase-12-Clinical-Study-of-A2B395-a-Novel-Allogeneic-Precision-CAR-T-Cell-Therapy-for-Patients-with-Solid-Tumors-that-Express-EGFR
09 Jan 2025
// BUSINESSWIRE
09 Nov 2024
// BUSINESS STD
Drugs in Development
Details:
The Proceeds will fund the company’s three clinical development programs and advancement of its pipeline of CAR-T cell therapies, which includes A2B530 is being evaluated for Pancreatic cancers.
Lead Product(s): A2B530
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: The Column Group
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 09, 2025
Lead Product(s) : A2B530
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : The Column Group
Deal Size : $80.0 million
Deal Type : Series C Financing
A2 Biotherapeutics Closes $80M Series C for Precision Cell Therapy
Details : The Proceeds will fund the company’s three clinical development programs and advancement of its pipeline of CAR-T cell therapies, which includes A2B530 is being evaluated for Pancreatic cancers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 09, 2025
Details:
A2B395 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): A2B395
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2024
Lead Product(s) : A2B395
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A2B395 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 12, 2024
Details:
A2B694 is an autologous logic-gated investigational cell therapy developed from A2 Bio’s proprietary Tmod™ platform. It is being evaluated for the treatment of mesothelin expressing cancers.
Lead Product(s): A2B694
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2024
Lead Product(s) : A2B694
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A2 Bio Doses First Patient In EVEREST-2 Trial Of Mesothelin CAR T
Details : A2B694 is an autologous logic-gated investigational cell therapy developed from A2 Bio’s proprietary Tmod™ platform. It is being evaluated for the treatment of mesothelin expressing cancers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 16, 2024
Details:
A2B694 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): A2B694
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Tempus
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2023
Lead Product(s) : A2B694
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Tempus
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A2B694 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 25, 2023
Details:
A2B530 consists of an activator that targets carcinoembryonic antigen (CEA) and a blocker that targets HLA-A*02, which is intended to provide selective killing of tumor tissues. It is being investigated for colorectal, pancreatic and non-small cell lung cancers.
Lead Product(s): A2B530
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2023
Lead Product(s) : A2B530
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A2B530 consists of an activator that targets carcinoembryonic antigen (CEA) and a blocker that targets HLA-A*02, which is intended to provide selective killing of tumor tissues. It is being investigated for colorectal, pancreatic and non-small cell lung ...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 30, 2023
Details:
A2B530 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): A2B530
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Tempus
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2023
Lead Product(s) : A2B530
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Tempus
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A2B530 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 21, 2023
Details:
A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity on normal tissues.
Lead Product(s): A2B530
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2022
Lead Product(s) : A2B530
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity o...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 07, 2022
Details:
A2B530 (Tmod CEA CAR T cell Therapy), selectively kill tumor cells while sparing normal cells, demonstrating the potential providing a radical new way to safely and effectively treat solid tumor cancers.
Lead Product(s): A2B530
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 02, 2022
Lead Product(s) : A2B530
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ ...
Details : A2B530 (Tmod CEA CAR T cell Therapy), selectively kill tumor cells while sparing normal cells, demonstrating the potential providing a radical new way to safely and effectively treat solid tumor cancers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 02, 2022
Details:
A2 will continue research and preclinical development of its undisclosed Tmod cell therapy candidate (its third candidate therapy), with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : A2 will continue research and preclinical development of its undisclosed Tmod cell therapy candidate (its third candidate therapy), with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 23, 2020
Details:
Proceeds will fund the advancement of its Tmod (T-cell module) platform and the clinical development and in-house manufacturing of its three near-term product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: The Column Group
Deal Size: $71.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 06, 2020
Details : Proceeds will fund the advancement of its Tmod (T-cell module) platform and the clinical development and in-house manufacturing of its three near-term product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
